BioLargo completes study of Breakthrough Water Treatment Technology for Poultry Process Water and Municipal Wastewater Treatment
Westminster CA – February 6, 2018 – BioLargo Inc. (OTCQB: BLGO) , an innovator of sustainable science and technology and full-service environmental engineering company, announced today the completion of a study that demonstrates the effectiveness of its Advanced Oxidation System (“AOS”) water treatment platform for treatment of poultry wastewater and municipal tertiary wastewater. The study was partially funded by the Metropolitan Water District (“MWD”) of Southern California’s Innovative Conservation Program (“ICP” – http://mwdh2o.com/ICP). A report of the study’s conclusions can be found online at MWD’s ICP website, http://www.bewaterwise.com/ICP_projects.shtml.
To highlight some conclusions in the report, the AOS was shown to:
To be at least 50% more energy-efficient in comparison to incumbent technologies (U.V. and Ozone);
Be forecasted to involve far less maintenance cost than chlorination; and
Could present an effective and cost-efficient alternative to market-available tertiary treatment technologies, and stands to afford major water and costs savings to the Californian municipal wastewater market;
These results complement the AOS’s prior proof-of-claim results that prove the AOS can:
Completely remove polyaromatic hydrocarbons;
Inactivate 6 logs of bacterial pathogens (Salmonella enterica and Escherichia coli);
Inactivate 4 logs of virus surrogate; and
Remove naphthenic acids (up to 80% in single pass).
BioLargo President and Chief Executive Officer Dennis Calvert commented, “This report demonstrates the enormous cost and water recycling benefits the AOS will have for end-users. We recently acquired a world-class team of engineers (www.BioLargoEngineering.com), to provide problem-solving solutions for clients and support the scale-up and commercial preparation for the AOS already underway. We are also evaluating a number of strategic alliance, public funding opportunities, pilots and customer opportunities for our AOS technology.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of sustainable science and technology, and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 55 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).
Safe Harbor StatementThe statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.
President and CEO